Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics (Premium)
$10.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shanghai Fosun Pharmaceutical (Group) Co Ltd's Sub-subsidiary to Acquire Equity Shares of Alma Lasers Ltd.


Friday, 26 Apr 2013 08:00pm EDT 

Shanghai Fosun Pharmaceutical (Group) Co Ltd announced that the Company's wholly owned sub-subsidiary, a Hong Kong-based company (Subsidiary A), and Subsidiary A's subsidiary, Chindex Medical Limited, have signed a share purchase agreement with Pramerica-Fosun China Opportunity Fund, L.P. (Pramerica-Fosun Fund), SISRAM MEDICAL LTD. (SISRAM), ALMA LASERS LTD, and ALMA LASERS LTD's shareholders, on April 26, 2013. According to the agreement, Subsidiary A will firstly inject USD 41,487,200 to increase its holdings in Chindex Medical from 51% to 70%, and then, Subsidiary A, Chindex Medical and Pramerica-Fosun Fund will respectively inject USD 44.42 million, USD 53.50 million and USD 50 million into SISRAM, to respectively hold a 30.03%, 36.17% and a 33.80% stake. After that, SISRAM will acquire 80% to 95.6% of Alma Lasers Ltd., which is an Israel-based medical and beauty equipment manufacturer.